GlassScriptPhysician profile
Nnamdi I Eze
NPI 1033370986
$7,636.69
in general payments reported to CMS, 2019-2025
50 companies · $1,489 in 2025
The $1,489 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,043 · 2020: $405 · 2022: $293 · 2023: $932 · 2024: $1,474 · 2025: $1,489.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,817 · Education: $78.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,816.92 |
| Education | $78.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $797.84 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $711.94 | 2019-2025 | Tagrisso, Lynparza, Calquence |
| Janssen Biotech, INC. | $467.98 | 2019-2025 | Erleada, Balversa, Akeega |
| Amgen INC. | $326.31 | 2019-2023 | Kyprolis |
| Novartis Pharmaceuticals Corporation | $319.06 | 2019-2025 | |
| Astellas Pharma US INC | $295.84 | 2019-2025 | Vyloy, Padcev |
| Genzyme Corporation | $247.39 | 2019-2024 | |
| Aveo Pharmaceuticals, INC. | $242.60 | 2022-2025 | Fotivda |
| Gilead Sciences, INC. | $240.23 | 2019-2025 | Trodelvy |
| Genentech USA, INC. | $238.61 | 2019-2025 | Phesgo, Perjeta, Kadcyla |
| Pfizer INC. | $225.46 | 2019-2025 | |
| Daiichi Sankyo INC. | $216.61 | 2019-2025 | Enhertu, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $212.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $202.40 | 2019-2025 | Opdualag, Krazati, Opdivo |
| Eisai INC. | $199.50 | 2019-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $198.95 | 2019 | |
| Exelixis INC. | $189.31 | 2019-2025 | Cabometyx |
| Incyte Corporation | $178.55 | 2019-2025 | Monjuvi, Zynyz, Pemazyre |
| Celgene Corporation | $162.98 | 2019-2025 | Reblozyl |
| Array Biopharma INC | $156.22 | 2019-2024 | Lorbrena, Xalkori, Braftovi |
| Taiho Oncology, INC. | $147.84 | 2019-2025 | |
| Glaxosmithkline, LLC. | $133.95 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Emd Serono, INC. | $114.79 | 2019-2025 | Bavencio |
| Pharmacyclics LLC, An Abbvie Company | $109.95 | 2019-2023 | Imbruvica |
| Seagen INC. | $108.48 | 2019 | |
| Alexion Pharmaceuticals, INC. | $107.09 | 2019-2025 | Ultomiris |
| Beigene USA, INC. | $102.14 | 2022-2024 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $94.01 | 2019-2024 | Iclusig, Alunbrig |
| Regeneron Healthcare Solutions, INC. | $91.88 | 2022-2025 | Libtayo |
| Lilly USA, LLC | $80.75 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Abbvie INC. | $70.34 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.28 | 2019-2024 | Gilotrif |
| Tersera Therapeutics LLC | $64.22 | 2023-2025 | Zoladex |
| Tesaro, INC. | $56.28 | 2019 | |
| Adc Therapeutics America, INC. | $55.82 | 2024-2025 | |
| Genmab U.S., INC. | $51.55 | 2024 | Epkinly |
| Pharmaessentia USA Corporation | $42.82 | 2024-2025 | Besremi |
| Ipsen Biopharmaceuticals, INC | $40.30 | 2019 | |
| Agios Pharmaceuticals, INC. | $30.88 | 2024-2025 | Pyrukynd |
| Teva Pharmaceuticals USA, INC. | $28.26 | 2019 | |
| Verastem, INC. | $25.56 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $25.22 | 2019 | |
| Foundation Medicine, INC. | $24.62 | 2019-2020 | |
| Azurity Pharmaceuticals, INC. | $24.21 | 2025 | Danziten |
| Rigel Pharmaceuticals, INC. | $22.10 | 2019 | |
| Geron Corporation | $21.45 | 2025 | Rytelo |
| Sumitomo Pharma America, INC. | $19.60 | 2024 | Orgovyx |
| Otsuka America Pharmaceutical, INC. | $17.41 | 2019 | |
| Dova Pharmaceuticals | $14.34 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nnamdi Eze listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.